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Low density lipoproteinAbstract Mushrooms have been highly regarded as possessing enormous nutritive and medicinal
values. In the present study, we evaluated the anti-oxidative and anti-atherosclerotic potential of
shiitake mushroom (Lentinula edodes) using its solvent–solvent partitioned fractions that consisted
of methanol:dichloromethane (M:DCM), hexane (HEX), dichloromethane (DCM), ethyl acetate
(EA) and aqueous residue (AQ). The hexane fraction (1 mg/mL) mostly scavenged (67.38%, IC50
0.55 mg/mL) the 2,2-diphenyl-1-picryl hydrazyl (DPPH) free radical, contained the highest reducing
capacity (60.16 mg gallic acid equivalents/g fraction), and most potently inhibited lipid peroxidation
(67.07%), low density lipo-protein oxidation and the activity of 3-hydroxy 3-methyl glutaryl
co-enzyme A reductase (HMGR). GC–MS analyses of the hexane fraction identified a-tocopherol
(vitamin E), oleic acid, linoleic acid, ergosterol and butyric acid as the bio-functional components
present in L. edodes. Our findings suggest that L. edodes possesses anti-atherosclerotic
bio-functionality that can be applied as functional food-based therapeutics against cardiovascular
diseases.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Food and food bio-components having anti-oxidative and
anti-hypercholesterolemic bio-functionalities have been highly
advocated as remedies for oxidative stress-induced pathophys-
iological complications (Orekhov et al., 2013). Atherosclerosis,
a cardiovascular disease (CVD) hallmark, has been intricately
linked with an oversupply of food-based cholesterol and exces-
sive production of oxidised low density lipoproteins (ox-LDL).
The International Atherosclerotic Society (IAS) formulatedy. Saudi
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demia, emphasising control of the level of LDL in order to
reduce the risk of atherosclerosis (Grundy et al., 2013). As
atherosclerosis is a long-term cause and effect process, anti-
atherosclerosis therapy should parallel its course. In this
endeavour, inhibitors of the key enzyme in cholesterol biosyn-
thesis, 3-hydroxy 3-methyl glutaryl co-enzyme A reductase
(HMGR), have been screened from micro-organisms followed
by their synthetic development designated as ‘‘statins”. But the
long-term use of statins and other cholesterol lowering drugs
seem inept when considering tachyphylaxis, drug toxicity and
cost management (Martin et al., 2012). In addition, not all
people can tolerate statins and their application comes with
some downside along with muscle aches upon discontinuation
(Karanth et al., 2013). In order to mitigate oxidative stress
towards LDL, boosting the anti-oxidative defence arsenal
has been suggested (Cherubini et al., 2005). In this connection,
food and food bio-component based approaches have received
due attention (Sirtori et al., 2009). The European Food Safety
Association (EFSA) recommended two types of functional
foods: phytosterol-based and b-glucan-based, for their potency
in reducing the risk of atherosclerosis en route to CVD (EFSA
Panel on Dietetic Products, Nutrition and Allergies, 2010).
These bio-components work by lowering the absorption of
cholesterol and/or curbing its biosynthesis. The anti-
oxidative mode of action of these bio-functional food compo-
nents can be divided into two broad spectra: electron transfer
(ET) and hydrogen atom transfer (HAT) through which the
anti-oxidant itself becomes a ‘‘less harmful oxidant for a
while” followed by its return to the main structural form with
the help of other ‘‘network anti-oxidants”, ultimately mitigat-
ing oxidative stress.
The macro fungi, mushrooms have been reported to possess
immense nutritional and medicinal bio-components and spur
excellence in maintaining global public health. Mushrooms
abound with phytosterol derivatives, including ergosterol and
fungisterol as well as b-D-glucan. The ergosterol concentration
in mushroom has been reported to be as high as 9.61 mg/g dry
weight (Kalacˇ, 2009; Mattila et al., 2002). b-D-glucan and its
derivatives present in both edible and medicinal mushrooms
confer their cholesterol lowering effects through reduced
absorption and/or increased faecal excretion (Cheung, 2010;
Wasser, 2011). The hypocholesterolemic effect of mushrooms
through their inhibitory role on HMG CoA-reductase has also
been documented (Gil-Ramı´rez et al., 2013; Rahman et al.,
2014). In addition, mushrooms have been highly regarded
for possessing anti-oxidative prowess (Cheung and Cheung,
2005; Abdullah et al., 2012).
Lentinus edodes, commonly known as the ‘‘shiitake mush-
room”, ranks second in the global mushroom market based
on consumer demand (Bisen et al., 2010). Its nutritional com-
ponents include bio-active polysaccharides such as b-D-glucan,
heteroglucan, xylomannan, lentinan and eritadenine; free sug-
ars including arabinose, arabitol, mannose, mannitol, tre-
halose and glycerol; vitamins (B2, B12, D2) and dietary fibre
(Hobbs, 2000). Numerous bio-components present in L. edo-
des aid in its pharmacological potency against hypertension,
hyperlipidemia and cardiovascular complications, depressed
immunity, hepatic disorders and cancer. In addition, its anti-
oxidative, anti-fungal and anti-microbial aspects have been
duly attributed to its bio-functional components (Bisen et al.,
2010). Although much work has been done on various aspectsPlease cite this article in press as: Rahman, M.A. et al., Lentinula edodes (shiitake mu
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anti-atherosclerotic effect through direct anti-oxidative and
inhibitory effects upon LDL oxidation and HMG Co-A reduc-
tase activity are scarce. Thus, the present work had been
designed to evaluate the anti-atherosclerotic potential of L.
edodes along with identifying the relevant bio-functional
components.
2. Materials and methods
2.1. Preparation of gradually partitioned solvent fractions of L.
edodes
Proper separation and purification of the functionally active
bio-components is an important criterion in demonstrating
their bio-functionality. Based on the polarity and density gra-
dient differences among five solvents (methanol, dichloro-
methane, ethyl acetate, hexane and water), we gradually
fractionated the mushroom bio-components following a
method described elsewhere (Rahman et al., 2014). Briefly,
L. edodes fruiting bodies were sliced, sun-dried and ground
to powder. Two hundred grams of powder was used for extrac-
tion with 4 L of methanol:dichloromethane (2:1) in conical
flasks at room temperature with occasional stirring and shak-
ing for 3 days followed by filtration through Whatman No. 1
filter paper. The extraction was repeated twice and the total
organic solution, collected from each step of extraction, was
evaporated using a rotary evaporator (Bu¨chi Rotavapor
R-114, Switzerland) that yielded the crude (M:DCM) extract.
The dried, crude extract was dissolved in 90% aqueous metha-
nol and partitioned with hexane (3  100 mL). The upper
hexane layer was separated using a separatory funnel and
later rota-evaporated. The bottom aqueous methanolic layer
left was rota-evaporated that yielded a semisolid fraction.
Re-dissolving of the semisolid fraction in distilled water
(100 mL) was followed by successive partitioning with dichlor-
omethane (DCM, 3  100 mL). We collected the partitioned
DCM fraction and rota-evaporated. Then, we re-partitioned
the aqueous fraction with ethyl acetate (EA, 3  100 mLs)
followed by collection of the resultant upper EA layer and
rota-evaporation. Finally, we freeze-dried the lower aqueous
part and obtained the aqueous fraction.
2.2. Evaluation of the anti-oxidant properties of L. edodes
fractions
We evaluated the anti-oxidative effects of the L. edodes frac-
tions compared with the positive control quercetin while carry-
ing out the standard tests described below.
2.2.1. Scavenging effect on 2,2-diphenyl-1-picrylhydrazil
(DPPH) radical
We followed a previously developed method in our lab for
determining the DPPH free radical scavenging effects of the
L. edodes fractions (Abdullah et al., 2012). In brief, 3.9 mL
of 0.06 mM DPPH dissolved in methanol was mixed with
0.1 mL of each solvent fraction (1.0 mg/mL conc.). After shak-
ing the mixture in darkness, we measured the absorbance at
515 nm. Using methanol as the blank, we calculated the per-
centage of DPPH free radical scavenging using the following
equation:shroom): An assessment of in vitro anti-atherosclerotic bio-functionality. Saudi
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where A0 is the absorbance of the 0.06 mM methanolic DPPH
alone, and As is the absorbance of the reaction mixture. The
IC50 value (concentration of the fraction necessary to produce
half maximal inhibition/scavenging) of the most potent solvent
fraction was calculated from the graph of the radical scaveng-
ing activity against fraction concentration.
2.2.2. Folin–Ciocalteu assay using the L. edodes fractions
Folin–Ciocalteu reagent (10%, 250 lL) was added to an equal
volume of the solvent fraction and kept at darkness for 3 min
while shaking. To this mixture, 500 lL of 10% sodium carbon-
ate was then added, followed by incubation in the dark for 1 h,
followed by measurement of the absorbance at 750 nm. The
calibration curve of gallic acid (2–10 lg/mL) was used to
express the performance of the Folin–Ciocalteu assay as mil-
ligrams of gallic acid equivalents (mg GAE) per gram of frac-
tion (Berger et al., 2004).
2.2.3. Inhibitory effects of the L. edodes fractions upon lipid
peroxidation
We applied our previously established method to determine
the inhibitory effect of each of the fractions on lipid peroxida-
tion of buffered egg yolk (Rahman et al., 2014). Briefly, Fowl
egg yolk was emulsified with 0.1 M phosphate buffer (pH 7.4)
to prepare a solution of 25 g/L. Lipid peroxidation was
induced by ferrous sulphate (1 M, 100 lL). The L. edodes frac-
tions (100 lL) were then added, shaken and incubated at room
temperature for 1 h. Then, 15% (v/v) of trichloroacetic acid
(TCA, 500 ll) and thiobarbituric acid (TBA, 1 mL), both
freshly prepared, were added. Following incubation in a boil-
ing water bath for 10 min, the reaction mixtures were cooled
and centrifuged at 3500g for 10 min to precipitate the proteins.
The absorbance of an aliquot of the supernatant (100 lL) was
measured at 532 nm. Buffered egg yolk with Fe+2 alone was
used as the control. Calculation of the percentage inhibition
of lipid peroxidation was performed according to the following
equation:
Inhibition ð%Þ ¼ ðA0  AsÞ  100=A0
where A0 is the absorbance of the control and As is the absor-
bance of the reaction mixture containing the fraction. The IC50
value of the most potent solvent fraction was calculated from
the graph of the inhibition of lipid peroxidation against frac-
tion concentration.
2.2.4. FeSO4–induced LDL oxidation and L. edodes fraction-
mediated inhibition
Following our previously established method, we determined
the L. edodes fraction-mediated inhibition of human LDL
(Sigma–Aldrich, St. Louis, USA) oxidation in vitro (Rahman
et al., 2014). The observed aspects included:
2.2.4.1. Effect of the L. edodes fractions upon the lag time of
conjugated diene (CD) formation. We induced Fe+2 (FeSO4,
50 lg/mL)-mediated oxidative stress towards human LDL
(150 lg/mL) at room temperature and pH 7.4. Subsequently,
we observed the kinetics of both Fe+2 – induced LDL oxida-
tion and the L. edodes fraction-mediated (1 lg/mL) corre-
sponding inhibition at 234 nm at 20 min intervals for aPlease cite this article in press as: Rahman, M.A. et al., Lentinula edodes (shiitake mu
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as the blank. Along the time course of oxidation, the L. edodes
fraction-mediated protection phase denoted as the ‘‘lengthened
lag time of CD formation” was identified and measured.
2.2.4.2. Effect of L. edodes fractions upon malondialdehyde
(MDA) production. Oxidative modification of human LDL
was performed using 10 mM ferrous sulphate followed by
the addition of L. edodes fractions at a 1 mg/mL concentra-
tion. Trichloroacetic acid (TCA, 500 lL, 15% v/v) and thio-
barbituric acid (TBA, 1 mL, 1% v/v) were added and
incubated at 100 C for 10 min. After cooling, an aliquot
(300 lL) was taken to the ELISA reader and the absorbance
read at 532 nm. For the blank, FeSO4 in water, pH 7.4, was
used. We used a standard assay kit (Cayman Chemicals’
TBARS assay kit, item No. 1000955) and followed the manu-
facturer’s recommendations to calculate the production of
MDA.
2.3. Determination of HMG Co-A reductase (HMGR)
inhibitory effect
The in vitro HMG Co-A reductase (HMGR) inhibitory effect
of the various fractions of L. edodes was tested using the
HMGR assay kit (Sigma-Aldrich, catalogue No. CS1090)
(Gholamhoseinian et al., 2010). The human catalytic domain
of the HMGR enzyme (concentration 0.6 mg protein/mL)
and pravastatin as a positive control were used according to
the recommended conditions. In order to attain a final mixture
of volume 200 lL and concentration 400 lM, 4 lL of NADPH
and 12 lL of HMG-CoA substrate were added with 2 lL of
the catalytic domain of human recombinant HMGR together
with an appropriate amount of 100 mM potassium phosphate
buffer (containing 120 mM KCl, 1 mM EDTA, and 5 mM
dithiothreitol, pH 7.4). Aliquots (1 lL) of pravastatin and L.
edodes fractions (1 mg/mL) were added and the rate of
NADPH oxidation by HMGR was monitored every 20 s at
340 nm for a period of 10 min using a Bio Tek H1 synergy
hybrid multi-mode plate reader equipped with Gen 5 data
analysis software (Bio Tek, VT, USA).
2.4. Identification of bio-functional components by GC–MS
As the hexane fraction of L. edodes showed the best perfor-
mance in terms of anti-oxidative and HMG Co-A reductase
inhibitory activities, it was subjected to GC–MS analysis to
identify the bio-functional and anti-atherosclerotic compo-
nents. We utilised gas chromatography directly coupled to a
mass spectrometer system (Agilent 7000 C triple quadruple
GC/MS system, USA). Utilising a HP-5 ms silica capillary col-
umn (30 m  250 lm, 0.25 lm film) the instrumental condi-
tions maintained were: oven temperature 70 C–300 C
(finally maintained for 29 min); inert helium gas as the carrier,
flow rate 1 mL/min; injection volume 1.5 lL; injection tech-
nique split less; injector temperature 250 C; ionisation energy
70 eV; mode electronic ionisation (EI); temperature of ion
source 200 C; range of masses scanned 50–550 m/z; and inter-
face line temperature 300 C. Mass spectra of the National
Institute of Standards and Technology (NIST 08 and
NIST08 s) library data were used as a reference to identify
the peaks.shroom): An assessment of in vitro anti-atherosclerotic bio-functionality. Saudi
Figure 2 Basic mechanisms of DPPH free radical scavenging by
the anti-oxidant molecule (AO-H).
4 M.A. Rahman et al.2.5. Statistical analyses
We conducted all the experiments in triplicate and the data are
presented as mean ± SD. Using statistical package SPSS ver-
sion 16 we performed one-way analysis of variance (ANOVA).
The differences among means were further analysed by the
least significance difference (LSD) test at a 95% confidence
level (p 6 0.05).
3. Results and discussion
3.1. DPPH-free radical scavenging activity
The DPPH-free radical scavenging performance of the L. edo-
des fractions was evaluated at a concentration of 1 mg/mL and
the results are presented in Fig. 1. All the fractions were cap-
able of scavenging free radicals but varied in their potency.
The hexane fraction had the highest scavenging activity
(67.38%, IC50 0.55 mg/mL), followed by that of DCM
(50.85%, IC50 0.68 mg/mL). The other three fractions did
not differ significantly in terms of DPPH free radical
scavenging.
The anti-oxidative test evaluating the scavenging effect of
the L. edodes fractions upon the DPPH free radical is an ET
based assay. All the fractions possessed free radical scavenging
potential but the scavenging effect of the hexane fraction sur-
passed that of all the others (Fig. 1). It measured the cumula-
tive antioxidant potential of the mushroom fractions whereby
the scavenging antioxidants present in the respective fractions
reduced the stable, purple radical DPPH_ and converted it into
the yellow coloured, non-radical form (DPPH-H) (Fig. 2).
3.2. Folin–Ciocalteu assay
The reducing capacity of the bio-components is a special fea-
ture of their anti-oxidative potency. In connection with this,
we performed the Folin–Ciocalteu assay compared to querce-
tin. Reducing prowess was expressed in terms of milligrams of
gallic acid equivalents per gram of fraction (mg GAE/g frac-
tion). The results are presented in Fig. 2, indicating the hexane
fraction possessed the highest reducing capacity (60.16 GAE/g0.00
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Figure 1 DPPH free radical scavenging effect of the L. edodes
fractions compared to the positive control, quercetin. Mean values
(n= 3) having dissimilar superscripts are indicative of a signifi-
cant statistical difference at the 95% level (p 6 0.05) following a
post hoc least significant difference (LSD) test.
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GAE/g fraction) and EA (55.32 mg GAE/g fraction).
The Folin–Ciocalteu assay performed in the present exper-
iment (Fig. 3) is another ET-based assay through which the
total reducing capacities of the L. edodes bio-components were
measured. The data presented in Fig. 2 are in line with a pre-
vious study undertaken by Abdullah et al. (2012). As com-
pared to the natural reducing agent gallic acid, L. edodes
showed promising results and thus we further studied its
effects upon lipid peroxidation and LDL oxidation.
3.3. Lipid peroxidation inhibitory effect
The inhibitory effect of the L. edodes fractions upon lipid per-
oxidation is shown in Fig. 3. We induced oxidative modifica-
tion of lipid structures with a transition metal, Fe+2, and
assessed whether the L. edodes fractions could lower the inhi-
bition or result in a reduced rate of oxidised lipid structural
byproduct generation. We found that the hexane fraction
had the most potent inhibitory effect on lipid peroxidation
(67.07%), followed by DCM (64.23%) (Fig. 4). This finding
was in line with the free radical scavenging and reducing
capacities of the fractions and suggested these effects might
be attributed to the lipophilic bio-components present in the
hexane fraction of L. edodes.
3.4. Inhibition of low density lipoprotein (LDL) oxidation by L.
edodes fractions
The kinetics of LDL oxidation incorporates an initial lag per-
iod of slow oxidation followed by a log period of enhanced
oxidation. During the lag period conjugated dienes (CD) are
formed, and during the log period malondialdehydes (MDA)0.00
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Figure 3 Folin–Ciocalteu assay of the L. edodes fractions
compared to the positive control, quercetin. Mean values
(n= 3) having dissimilar superscripts are indicative of a signifi-
cant statistical difference at the 95% level (p 6 0.05) following a
post hoc least significant difference (LSD) test.
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Figure 4 Lipid peroxidation inhibitory effect of L. edodes
fractions compared to the positive control, quercetin. Mean
values (n= 3) having dissimilar superscripts are indicative of a
significant statistical difference at the 95% level (p 6 0.05)
following a post hoc least significant difference (LSD) test.
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In vitro anti-atherosclerotic bio-functionality 5are generated (Yoshida and Kisugi, 2010). The anti-
atherosclerotic performance of bio-components involves their
mediating effect upon increasing the lag time and decreasing
MDA production (Li and Mehta, 2005). The hexane fraction
of L. edodes also performed the best in this regard.
3.4.1. Effect of L. edodes fractions upon the lag time of CD
formation
Oxidative stress exerted upon LDL molecules by Fe+2 affects
the polyunsaturated fatty acids (PUFAs) present in the LDL
molecule and produces conjugated dienes (CD). Fig. 5 repre-
sents the kinetics of CD production and the effect of L. edodes
fractions upon this kinetic pattern. The hexane fraction length-
ened the lag time (125 min) of CD formation the most, indicat-
ing it possessed the highest inhibitory activity against LDL
oxidation.
3.4.2. Effect of L. edodes fractions upon MDA formation
In the LDL oxidation cascade, CD formation is rapidly fol-
lowed by the production of MDA through the breakage of
the lipid hydro-peroxide double bonds. Thus, the level of
MDA corresponds to the severity of LDL oxidation. We
found that all L. edodes fraction-treated samples had a lower0
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Figure 5 Kinetics of conjugated diene (CD) formation. L. edodes
fractions mediated an increased lag time of CD formation at
234 nm, indicating their inhibitory effect on FeSO4-induced LDL
oxidation. All the fractions and the positive control, quercetin,
were used at a 1 lg/mL conc.
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Among all the solvent fractions of L. edodes, the hexane frac-
tion rendered the smallest amount of MDA (21.57 lM/mg
LDL), indicating it had the highest content of bio-
components capable of withstanding LDL oxidation.
3.5. Inhibitory effect of L. edodes fractions upon HMG Co-A
reductase (HMGR) activity
We assessed whether the L. edodes fractions could inhibit the
activity of the cholesterol biosynthetic regulatory enzyme
HMG Co-A reductase (HMGR) in vitro. All the fractions
could inhibit the activity of the catalytic domain of human
HMGR at 1 mg/mL concentration. As depicted in Fig. 6, here
also, the hexane fraction-mediated inhibitory effect was the
most potent (44.26%).
An increased level of total cholesterol is an independent risk
factor for atherosclerosis. Interruption of cholesterol biosyn-
thesis through direct inhibition of its regulatory enzyme
HMG Co-A reductase has been a target for the last few dec-
ades. We also evaluated whether L. edodes could inhibit
HMG Co-A reductase activity in vitro. Consistent with our
other findings, the hexane fraction of L. edodes inhibited the
activity of HMG Co-A reductase the most (44.26%) as com-
pared to the synthetic statin drug pravastatin (87.64%). The
anti-oxidative effect of the statin drugs has been regarded as
conferring their anti-atherosclerotic effect (Puttananjaiah
et al., 2011). L. edodes possesses the top-ranking position
among 26 different edible and medicinal mushrooms in terms
of exerting inhibitory effects towards HMG Co-A reductase
activity (Gil-Ramı´rez et al., 2013a,b). However, different parts
of the mushroom body differ from one another in terms of
potency, with the L. edodes cap possessing the best HMG
Co-A reductase inhibitory activity.
3.6. Identification of the anti-atherosclerotic bio-functional
components by GC–MS
The bio-functional components in the hexane fraction of
L. edodes that exhibited anti-atherosclerotic effects were0.00
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Figure 6 Inhibitory effect of L. edodes fractions (1 mg/mL) on
HMG Co-A reductase (HMGR) activity compared to the positive
control, pravastatin (used directly according to the manufacturer’s
recommendation). Mean values (n= 3) having dissimilar super-
scripts are indicative of a significant statistical difference at the
95% level (p 6 0.05) following a post hoc least significant
difference (LSD) test.
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6 M.A. Rahman et al.identified through GC–MS analyses. The chromatograph
presented in Fig. 7 demonstrates the peaks of the identified
bio-components. Among them, the most abundant were
a-tocopherol (vitamin E), oleic acid, linoleic acid, ergosterol
and butyric acid (Table 1).
GC–MS analysis identified the presence of the chain break-
ing anti-oxidant a-tocopherol (vitamin E) in the hexane frac-
tion. The inhibitory effect of L. edodes towards LDL
oxidation observed in the present study might be attributed
to the a-tocopherol content of this mushroom. Vitamin E scav-
enges free radicals by following hydrogen atom transfer (HAT)
mechanism. It reacts with a free radical such as a lipid peroxyl
molecule and interrupts further peroxidation by producing a
hydroperoxide and a radical form of a-tocopherol. Both of
these intermediates are less harmful as they are almost unreac-
tive. The radical form of a-tocopherol can either react with
another peroxyl molecule to turn into a functionally unreactive
product or revert back to its original functional form of vita-
min E (Fig. 8).
Despite some exceptions, studies involving animal models
and clinical trials as well as human epidemiological dataFigure 7 GC–MS chromatograph of
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Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01.021suggest the protective role of a-tocopherol against atheroscle-
rosis (O’Byrne et al., 2002; Munteanu et al., 2004). Vitamin
E was able to reduce atherosclerotic lesions up to 60% in
experimentally induced atherosclerosis-prone mice (Peluzio
et al., 2001; Schwenke et al., 2002). Its anti-atherosclerotic role
in hypercholesterolemic rabbits has also been documented
(Schwenke et al., 2002). At physiological concentrations
(10–30 lM), a-tocopherol could lengthen the lag time of CD
formation from 59.6 to 98.9 min (Baldi et al., 2003).
Ergosterol, another bio-component identified in the hexane
fraction of L. edodes, has been suggested to act as a membrane
antioxidant upon ingestion. Ohnuma et al. (2000) isolated and
elucidated the structural features of ergosterol from L. edodes.
The inhibitory effect of ergosterol peroxide isolated from the
mushroom Armillariella mellea on lipid peroxidation was
greater than those of a-tocopherol and thiourea (Wiseman
et al., 1993). Supplementation of ergosterol and oleic acid in
medium containing Saccharomyces cerevisiae has been
reported to lower the production of reactive oxygen species,
oxidative stress and the resultant damage at the cellular and
biomolecular levels (Ohnuma et al., 2000). Ergosterol peroxidethe hexane fraction of L. edodes.
shroom): An assessment of in vitro anti-atherosclerotic bio-functionality. Saudi
Table 1 Identification of the bio-active components of the hexane fraction of L. edodes by GC–MS.
No Bio-component Structure Molecular formula Molecular weight (g)
1 a-Tocopherol C29H50O2 430.71
2 Oleic acid O
OH
C18H34O2 282.46
3 Linoleic acid
O
OH
C18H32O2 280.45
4 Ergosterol
CH3
HO
H
CH3
3C
CH3
CH
CH3
3
C28H44O 396.65
5 Butyric acid C4H8O2 88.11
Figure 8 Basic mechanisms demonstrating the lipid peroxidation
inhibitory effect of a-tocopherol.
In vitro anti-atherosclerotic bio-functionality 7and ergosterol have been reported to suppress LPS-induced
inflammatory responses through inhibiting NF-kB and
C/EBPb transcriptional activity, and phosphorylation of
MAPKs (Kim et al., 1999). Mushrooms’ antioxidant effects
relating to DPPH free radical scavenging and Folin–Ciocalteu
assay (reducing capacity test) has been attributed towards its
content of different bio-components (Landolfo et al., 2010).
However, anti-oxidative performance varies depending on
mushroom species and also based on the extracting solvent uti-
lised. In case of polar solvent-based mushroom bioseparation,
phenolic and polyphenolic group of reducing substances have
been regarded for providing with DPPH free-radical scaveng-
ing and Folin–Ciocalteu assay performance while triterpenoids
have been linked with metal chelating activities (Landolfo
et al., 2010; Kobori et al., 2007). For non-polar solvent suchPlease cite this article in press as: Rahman, M.A. et al., Lentinula edodes (shiitake mu
Journal of Biological Sciences (2016), http://dx.doi.org/10.1016/j.sjbs.2016.01.021as hexane, ergosterol has been identified as the principal
anti-oxidative mushroom bio-component (Kalogeropoulos
et al., 2013). Thus, 5,6-dihydroxy ergosterol and structurally
relevant components such as 7,22-ergostadienol, ergosta
7,22-dien-3-ol present in the hexane fraction might have been
involved in chelating transition metal ion, Fe+2 and thus medi-
ating reduced oxidative stress and consequent lowered LDL
oxidation. In case of Grifola frondosa, the anti-oxidative pat-
tern of ergosterol has been documented to be second only to
fatty acids (Nieto and Chegwin, 2008).
Fatty acids are important functional bio-components of
both edible and medicinal fungi. In the hexane fraction of L.
edodes we identified the presence of oleic acid, linoleic acid
and butyric acid. Oleic acid is a monounsaturated fatty acid
that has been reported to provide anti-atherosclerotic effects
in different diets, especially the Mediterranean diet (Shao
et al., 2010). Its anti-atherosclerotic mode of action involves
dampening of endothelial activity by reducing the expression
of vascular cell adhesion molecule – 1 (VCAM-1) and the
activity of NF–Kb (Zhang et al., 2002). As a result, the adher-
ence of monocytes to endothelial walls is reduced and the asso-
ciated pro-inflammatory and pro-atherogenic processes slowed
down. Butyric acid, another short chain fatty acid found in the
L. edodes fraction, has also been reported to confer an
anti-atherosclerotic effect through modulating VCAM-1 and
NF-jB activity (Massaro et al., 1999).
Linoleic acid (LA, cis-9, cis-12 octadecadienoic acid) has
been among the most abundant fatty acids found in some
other species of edible mushrooms (Kalogeropoulos et al.,
2013). Linoleic acid and its constitutional and stereoisomersshroom): An assessment of in vitro anti-atherosclerotic bio-functionality. Saudi
8 M.A. Rahman et al.termed ‘‘conjugated linoleic acid (CLA)” have become an
attractive subject of anti-atherosclerotic studies. Research
involving the effects of linoleic acid upon animal models has
demonstrated its considerable inhibitory effect on the estab-
lishment and progression of atherosclerosis. Dietary supple-
mentation of conjugated linoleic acid (CLA) could lower
blood levels of LDL and triacylaglyceride as well as slow down
the progression of atherosclerotic lesion formation (Carluccio
et al., 1999). The proposed mechanism involved CLA-
induced enhanced expression of the nuclear transcription fac-
tor peroxisome proliferator activated receptor c (PPARc),
especially in vascular smooth muscle cells. Although some
in vitro studies indicate a pro-oxidative and pro-atherogenic
role of linoleic acid, compelling in vivo evidence has yet to be
established. In human subjects, linoleic acid rich diets have
been credited with reducing the risk of coronary heart diseases
(Zapolska-Downar et al., 2004).
Inhibitory effect towards the activity of HMG Co-A reduc-
tase might also be attributed to ergosterol present in the hex-
ane fraction of L. edodes. Our proposition is backed by the
findings of both in vitro, ex vivo and in vitro studies (Rudel,
1999; Kritchevsky et al., 2000; Gil-Ramı´rez et al., 2013a,b).
Ergosterol peroxide from the edible mushroom Sarcodon
aspratus, had been found to down-regulate the expression of
low-density lipoprotein receptor (LDLR) and HMG-CoA
reductase (HMGCR) genes in RAW264.7 cells (Kim et al.,
1999). Supplementation of ergosterol and oleic acid in the
medium containing Saccharomyces cerevisiae had been
reported to lower the production of reactive oxygen species,
oxidative stress and the resultant damage towards cellular
and biomolecular levels (Ohnuma et al., 2000). The HMG
Co-A reductase inhibitory effect is mediated by the statins.
Contrary to the established notion of the statins for hypoc-
holesterolemic performance, the present study reports a differ-
ent mechanistic approach of the mushroom bio-components.
As the present study had not searched for the presence of sta-
tins in the L. edodes fractions, this remains as an important
scope of our future studies.
4. Conclusion
L. edodes (shiitake mushroom) has been found possessing bio-
active food components capable of conferring anti-oxidative
defence and curtailing LDL oxidation as well as being potent
in inhibiting the activity of the rate limiting enzyme in
cholesterol biosynthesis, thus supporting its use as an
anti-atherosclerotic agent. Food bio-components including
a-tocopherol (vitamin E), oleic acid, linoleic acid, ergosterol
and butyric acid present in L. edodes enabled it to act as an
anti-atherosclerotic agent. The current findings can be further
explored in in vivo models to substantiate the therapeutic use
of L. edodes with a view to aiding atherosclerosis-affected peo-
ple around the world.
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